[go: up one dir, main page]

AR009805A1 - PEPTIDES CONTAINING CYSTEINE - Google Patents

PEPTIDES CONTAINING CYSTEINE

Info

Publication number
AR009805A1
AR009805A1 ARP970104369A ARP970104369A AR009805A1 AR 009805 A1 AR009805 A1 AR 009805A1 AR P970104369 A ARP970104369 A AR P970104369A AR P970104369 A ARP970104369 A AR P970104369A AR 009805 A1 AR009805 A1 AR 009805A1
Authority
AR
Argentina
Prior art keywords
pro
proline
side chains
amino acid
glu
Prior art date
Application number
ARP970104369A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR009805A1 publication Critical patent/AR009805A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un péptido fisiologicamente activo de formula (I): A-(R1)x-R2-Cys-R3-B, en la cual cada A se selecciona independientemente entre H, un grupo protector, opor lo menos un residuo aminoácido seleccionado independientemente entre el grupo de residuos aminoácidos que tienen cadenas laterales alifáticas, cadenaslaterales oxhidrilo alifáticas, cadenas laterales básicas, cadenas laterales acídicas, grupos amino secundario, cadenas laterales amida, cadenas lateralesaromáticas y cadenas lateralescon contenido de azufre; x es 0 (estando ausente R1) y R2 y R3 son residuos de aminoácidos seleccionados entre una de lassiguientes combinaciones (a) y (b) de aminoácidos: (a) R2 leucina (Leu), R3 fenilalanina (Phe); (b) R2 glutamina (Gln), R3 alanina (Ala), o x es 1, y R1,y R2 y R3 son residuos de aminoácidos elegidos entre una de las siguientes combinaciones (c) y (f) a (s) de aminoácidos: (c) R1 ácido glutámico (Glu), R2prolina (Pro), R3 metionina (Met); (f) R1 alanina (Ala), R2 prolina (Pro), R3 metionina (Met); (g) R1 ácido glutámico (Glu), R2 prolina (Pro), R3 triptofano(Trp); (h) R1 serina (Ser), R2 prolina (Pro), R3 triptofano (Trp), (i) R1 leucina (Leu), R2 leucina (Leu), R3 glicina (Gly); (j) R1 prolina (Pro), R2arginina (Arg), R3 arginina (Arg); (k) R1 glicina (Gly), R2 tirosina (Tyr), R3 prolina (Pro); (l) R1 valina (Val), R2 valina (Val), R3 asparagina (Asn); (m)R1 alanina (Ala), R2 leucina (Leu), R3 arginina (Arg); (n) R1 glicina (Gly), R2 alanina (Ala),R3 prolina (Pro); (o) R1 lisina (Lys), R2 serina (Ser), R3lisina (Lys); (p) R1 ácido glutámico (Glu), R2 (Pro), R3 fenilalanina (Phe); (q) R1 ácido glutámico (Glu), R2 prolina (Pro), R3 tirosina (Tyr); (r) R1serina (Ser), R2 prolina (Pro), R3 metionina (Met); (s) R1 glicina (Gly), R2 prolina (Pro), R3 triptofano (Trp); con las condiciones de que, cuando x es OA physiologically active peptide of formula (I): A- (R1) x-R2-Cys-R3-B, in which each A is independently selected from H, a protecting group, or at least one amino acid residue independently selected from the group of amino acid residues having aliphatic side chains, aliphatic hydroxy side chains, basic side chains, acidic side chains, secondary amino groups, amide side chains, aromatic side chains and sulfur-containing side chains; x is 0 (R1 is absent) and R2 and R3 are amino acid residues selected from one of the following amino acid combinations (a) and (b): (a) R2 leucine (Leu), R3 phenylalanine (Phe); (b) R2 glutamine (Gln), R3 alanine (Ala), ox is 1, and R1, and R2 and R3 are amino acid residues chosen from one of the following combinations (c) and (f) to (s) of amino acids : (c) R1 glutamic acid (Glu), R2proline (Pro), R3 methionine (Met); (f) R1 alanine (Ala), R2 proline (Pro), R3 methionine (Met); (g) R1 glutamic acid (Glu), R2 proline (Pro), R3 tryptophan (Trp); (h) R1 serine (Ser), R2 proline (Pro), R3 tryptophan (Trp), (i) R1 leucine (Leu), R2 leucine (Leu), R3 glycine (Gly); (j) R1 proline (Pro), R2arginine (Arg), R3 arginine (Arg); (k) R1 glycine (Gly), R2 tyrosine (Tyr), R3 proline (Pro); (l) R1 valine (Val), R2 valine (Val), R3 asparagine (Asn); (m) R1 alanine (Ala), R2 leucine (Leu), R3 arginine (Arg); (n) R1 glycine (Gly), R2 alanine (Ala), R3 proline (Pro); (o) R1 lysine (Lys), R2 serine (Ser), R3lisin (Lys); (p) R1 glutamic acid (Glu), R2 (Pro), R3 phenylalanine (Phe); (q) R1 glutamic acid (Glu), R2 proline (Pro), R3 tyrosine (Tyr); (r) R1serine (Ser), R2 proline (Pro), R3 methionine (Met); (s) R1 glycine (Gly), R2 proline (Pro), R3 tryptophan (Trp); with the conditions that, when x is O

ARP970104369A 1996-09-23 1997-09-23 PEPTIDES CONTAINING CYSTEINE AR009805A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603466A SE9603466D0 (en) 1996-09-23 1996-09-23 New compounds

Publications (1)

Publication Number Publication Date
AR009805A1 true AR009805A1 (en) 2000-05-03

Family

ID=20403988

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104369A AR009805A1 (en) 1996-09-23 1997-09-23 PEPTIDES CONTAINING CYSTEINE

Country Status (5)

Country Link
AR (1) AR009805A1 (en)
AU (1) AU4406197A (en)
SE (1) SE9603466D0 (en)
WO (1) WO1998012213A2 (en)
ZA (1) ZA978477B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005218555B2 (en) 2004-03-01 2008-01-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
EP2079309B1 (en) * 2007-04-12 2015-11-11 Joyant Pharmaceuticals Inc Smac mimetic dimers and trimers useful as anti-cancer agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0142387A1 (en) * 1983-08-26 1985-05-22 Anda Biologicals Process for the preparation of vaccines specific for LH and HCG and process for their detection
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
JPH07509221A (en) * 1992-04-13 1995-10-12 オクラホマ メディカル リサーチ ファウンデーション Methods and reagents for autoantibody diagnosis
EP0664711A1 (en) * 1992-09-08 1995-08-02 Centocor Inc. Peptide inhibitors of cellular adhesion
SE9403526D0 (en) * 1994-10-14 1994-10-14 Astra Ab New Peptides
AU4146796A (en) * 1994-10-27 1996-05-23 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from ambrosia artemisiifolia
WO1997039023A1 (en) * 1996-04-12 1997-10-23 Astra Aktiebolag Cysteine-containing or methioine-containing peptides with immunomodulatory effects

Also Published As

Publication number Publication date
WO1998012213A3 (en) 1998-04-30
AU4406197A (en) 1998-04-14
SE9603466D0 (en) 1996-09-23
WO1998012213A2 (en) 1998-03-26
ZA978477B (en) 1998-03-23

Similar Documents

Publication Publication Date Title
ATE158305T1 (en) ANTIAGGREGATIVE PEPTIDES
TW343198B (en) Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them
HUP9903530A2 (en) Antiangiogenic peptides derived from plasminogen
KR850007801A (en) Method of producing polypeptide
DE69325178D1 (en) INHIBITORS ACTIVATED BY PEPTIDYLKETONE AND CONTAINING NATURAL AND NON-NATURAL PEPTIDE SEQUENCES
JP2006525288A5 (en)
NL300013I1 (en) New protein with TNF-inhibiting effect and their ber
NO942553L (en) New Kunitz-type human protease inhibitor and variants thereof
NZ333606A (en) Isolated peptides derived from MAGE-2
ATE245999T1 (en) AMINO ACID COMPOSITIONS
ES2054365T3 (en) INHIBITION OF THE ROUTE OF THE FINAL N RULE IN LIVING CELLS.
CY1112839T1 (en) X-CONOXOTINE Peptides having an N-terminal Pyroglutamic Acid
AR009807A1 (en) PEPTIDES CONTAINING ANALOGS OF CYSTEINE.
JPS5594934A (en) Peptide type polymer and pharmaceutic composition containing it
AR009805A1 (en) PEPTIDES CONTAINING CYSTEINE
ATE42308T1 (en) PHARMACOLOGICALLY ACTIVE PEPTIDES.
ATE124955T1 (en) SUBSTRATE PEPTIDES.
ATE30919T1 (en) GASTROGENIC PEPTIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THEM.
DE3782880D1 (en) INHIBITIVE PEPTIDES.
Asp et al. fraction A of pig insulin (PAC): pyridine-acetate buffer
UA28084C2 (en) Antitumoral agent, isolated from intestine mucous membrane, method of its isolation